Medical Health & Life Science Research News

New findings help explain how usher syndrome affects vision and hearing, pipeline review 2022

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline Usher Syndrome - Pipeline Review, H1 2017, an overview of the Usher Syndrome (Genetic Disorders) pipeline landscape.

Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigments.

Risk factors include retinal degeneration, prolonged, unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing and Vitamin A supplementation.

Global Markets Directs Pharmaceutical and Healthcare latest pipeline Usher Syndrome – Pipeline Review, H1 2017, comprehensive information on the therapeutics under development for Usher Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.


The Usher Syndrome (Genetic Disorders) pipeline also reviews of key players involved in therapeutic development for Usher Syndrome and features dormant and discontinued projects. It covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Discovery stages are 2 and 3 respectively.

Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Usher Syndrome (Genetic Disorders) pipeline helps in report identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. This built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.



  • Snapshot of the global therapeutic landscape of Usher Syndrome (Genetic Disorders).
  • Reviews pipeline therapeutics for Usher Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • Features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews key companies involved in Usher Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • Evaluates Usher Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • Encapsulates all the dormant and discontinued pipeline projects.
  • Reviews latest news related to pipeline therapeutics for Usher Syndrome (Genetic Disorders)

News From

Research N ReportsResearch N Reports
Category: Market Research Publishers and RetailersCompany about: Research N Reports is a new age market research firm where we focus on providing information that can be effectively applied. Today being a consumer driven market, companies require information to deal with the complex and dynamic world of choices. Where relying on a sound board firm for your decisions becomes crucial.   Research N Reports specializes in industry analysis, market forecasts and as a result getting quality reports covering all verticals, whether be it gaining perspective on ...
This email address is being protected from spambots. You need JavaScript enabled to view it.